Summary & Overview
HCPCS J9352: Injection, Trabectedin 0.1 mg
HCPCS Level II code J9352 represents the injectable antineoplastic agent trabectedin, billed in increments of 0.1 mg. This drug-specific code is used when reporting administration of trabectedin in oncology care and is relevant for facility and professional billing in outpatient infusion settings. Nationally, precise coding of high-cost oncology drugs like trabectedin affects payment accuracy, utilization tracking, and access to specialty therapies.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9352 denotes clinically and operationally, typical sites of service for administration, and which major payers are part of the comparative review. The publication outlines benchmarks and coverage patterns where available, summarizes relevant billing practices for oncology infusions, and highlights policy updates and payer considerations that influence reimbursement and prior authorization workflows.
This summary is intended to orient billing staff, oncology pharmacists, and revenue cycle managers to the clinical purpose of the code, the payer landscape, and the types of benchmarking and policy content included in the full publication. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J9352 describes the drug injection of trabectedin, billed per 0.1 mg unit. This code is used to report administration of trabectedin, an antineoplastic agent, for oncology treatment.
Service Type: Injection, chemotherapy/antineoplastic agent administration
Typical Site of Service: Outpatient infusion center or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J9352 (Injection, trabectedin, 0.1 mg) is an adult oncology patient with advanced soft tissue sarcoma, often liposarcoma or leiomyosarcoma, who has progressed on prior chemotherapy regimens. The clinical workflow begins with an oncology clinic evaluation documenting diagnosis, performance status, prior therapy, baseline labs (CBC, CMP, liver function tests), and consent for chemotherapy. On the day of treatment the patient arrives to an outpatient infusion center or hospital outpatient department for intravenous administration. Pre-infusion nursing assessment includes vital signs, review of labs to ensure acceptable neutrophil and hepatic function, and review of premedications (antiemetics, corticosteroids if used per protocol). Trabectedin is administered intravenously over the recommended infusion duration (per institutional protocol) with chemotherapy-certified nursing staff and oncology pharmacist verification of dose based on mg/kg or body surface area and vial concentrations. During infusion, the patient is monitored for infusion reactions and hematologic or hepatic toxicity. Post-infusion monitoring includes observation for delayed adverse events, scheduling follow-up labs prior to the next cycle, and documentation of treatment date, administered units of J9352, lot numbers, and any applicable modifier(s). Typical site of service is an outpatient infusion center or hospital outpatient department. Common payer interactions and prior authorization may occur with payors such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|